As a recombinant anti-EGFR/CD3 bispecific antibody developed by Zhejiang Shimai Pharmaceutical Co., Ltd., SMET12 directs T cell activation to kill EGFR-positive tumor cells through binding to EGFR on tumor cell surface and CD3 receptor on T cell surface (24). This evidence concerns the gene EGFR and neoplasm.